Rubius Therapeutics: Pioneering a New Era of Cellular Therapies

BY Sean Smith
November 15, 2018

Rubius Therapeutics is harnessing the inherent properties of red blood cells to develop the next generation of cellular therapies. At the 2018 Benchling User Forum, Tiffany Chen, Director of Discovery at Rubius Therapeutics, discussed the unique data problems presented by red blood cell therapies, and how Benchling is changing the way that Rubius organizes and carries out R&D. Rubius is using Benchling across discovery and service teams to power collaboration and add context to requests and experimental results.

Visit our Customer Stories page to learn more about how companies use Benchling to accelerate their biologics R&D.

View the full Rubius Therapeutics Case study on our website.

Published by Sean Smith
VIEW ALL POSTS BY Sean Smith

Leave a Reply

%d bloggers like this: